Cita APA

SANCHO, J., Kumar, A., Cordoba, R., Tani, M., Langmuir, P., & Abrisqueta, P. (2024). Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: Analysis of a phase 1 dose-finding study (CITADEL‑112).

Citación estilo Chicago

SANCHO, JUAN-MANUEL, Abhijeet Kumar, Raul Cordoba, Monica Tani, Peter Langmuir, y Pau Abrisqueta. Safety and Efficacy of Parsaclisib in Combination With Rituximab, Bendamustine + rituximab, or Ibrutinib in Patients With Previously Treated B-cell Lymphoma: Analysis of a Phase 1 Dose-finding Study (CITADEL‑112). 2024.

Cita MLA

SANCHO, JUAN-MANUEL, et al. Safety and Efficacy of Parsaclisib in Combination With Rituximab, Bendamustine + rituximab, or Ibrutinib in Patients With Previously Treated B-cell Lymphoma: Analysis of a Phase 1 Dose-finding Study (CITADEL‑112). 2024.